Kinfo
Senseonics Holdings, Inc. logo

Senseonics Holdings, Inc.

SENSNYSEHealthcare·US · USD
$5.94
+0.22 (+3.76%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap309.82M USD
Enterprise value217.89M USD
Trailing P/E-3.58
Forward P/E-2.61
PEG ratio-0.00
Price / sales7.33
Price / book3.87
Profitability
Gross margin59.26%
Operating margin-271.93%
Profit margin-214.16%
Return on assets-57.02%
Return on equity-250.78%
Income (TTM)
Revenue40.71M USD
Gross profit21.20M USD
EBITDA-85.02M USD
Net income-87.19M USD
Diluted EPS-$1.97
Rev. growth (YoY)87.20%
Balance sheet
Total cash64.32M USD
Total debt43.14M USD
Debt / equity125.65
Current ratio3.51
Book value / share$1.48
Cash flow (TTM)
Operating cash flow-75.07M USD
Levered free cash flow-56.31M USD
Shares & price
Shares outstanding41.80M
Float38.54M
Held by institutions21.05%
Beta0.97
50-day MA$6.37
200-day MA$6.99
52-week high$12.58
52-week low$4.79
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a commercial-stage medical technology company specializing in long-term, implantable continuous glucose monitoring systems for people with diabetes in the United States and internationally. The company’s Eversense product family, including Eversense, Eversense XL, Eversense E3, and Eversense 365, uses a small sensor inserted under the skin, a removable and rechargeable smart transmitter worn on the body, and a mobile application that delivers real-time glucose readings and alerts. These systems are designed to provide extended wear duration compared with traditional transcutaneous CGM devices, supporting continuous monitoring without frequent sensor replacement. Senseonics focuses on the development and manufacturing of these glucose monitoring products and distributes them through healthcare providers, distributors, and strategic commercial partners, serving the global diabetes community. Headquartered in Germantown, Maryland, Senseonics plays a specialized role in the medical technology and diabetes care market by offering differentiated implantable CGM solutions intended to support more informed and convenient day-to-day glucose management.

Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Timothy T. Goodnow Ph.D.
Employees
130
Headquarters
Germantown, MD, United States

Frequently asked questions about Senseonics Holdings, Inc.